Canada has confirmed the phased introduction of new fragrance allergen labeling requirements for cosmetic products, a change relevant to all brands that operate or want to operate in this market.

This regulatory move is part of a broader FDA effort to modernize the monograph system for over-the-counter drugs—including sunscreens—and promote scientific innovation in sun protection formulations. Although the proposal remains open for public comment until January 2026, its progress has already generated interest among formulators and dermatologists, who see bemotrizinol as a tool for delivering more effective formulations with an improved sensory profile.

The EPA proposes changes to the PFAS reporting rule under TSCA in the US, introducing exemptions and shorter deadlines. Comments open until December 2025.

ECHA submitted its 12th recommendation to the European Commission to add four substances to the REACH authorization list (Annex XIV). These substances come from the list of “SVHC” (substances of very high concern) and have been selected as high priority due to their potential risks to human health or the environment.

Over-the-counter (OTC) products are one of the main areas where the US market differs from the rest of the world. A sunscreen, antiperspirant, or acne treatment may seem like simple cosmetics from a brand's international perspective, but for the FDA, they fall under the OTC ("over-the-counter") classification , which in the United States is regulated as drugs .